Innovating Works

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Activa
Mostrando 1 al 20 de 114 resultados
CARLY: Development and characterization of a novel CAR T-cell therapy for NHL FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughout the body. The standard of care for patients with aggressiv...
2024-03-26 | Financiado
FUN-HSC: TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells. They are a life-saving therapy for leukemia and have recently found broadened applications to gene and cell therapy,...
2023-11-15 | Financiado
BiTE-CAR: CD22/CD19 dual redirection Dual targeting of CD22 and CD19 with BiTE-secreting and CAR-expressing bispecific T-cells for adoptive Cellular ImmunoTherapy in advanced B-cell Acute Lymphoblasti FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: Anti-CD19 immunotherapies based on Bi-specific T-cell Engagers (BiTE) or chimeric antigen receptor (CAR)-expressing T-cells have revolutionized the treatment of refractory/relapse (R/R) B-cell acute l...
2023-04-05 | Financiado
ChroMet: Elucidating the role of macroH2A1.2 histone variant as a metabolic sensor in the epigenetic regulation of leukaemia cell fate. FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: The initiation and maintenance of leukaemia are often regulated through the interaction of epigenetic mechanisms and metabolism, but how these affect each other, is not always fully understood. One of...
2023-03-21 | Financiado
CARxALL: Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia ONECHAIN IMMUNOTHERAPEUTICS SL tramitó un HORIZON EUROPE: R/R T-ALL remains a major clinical challenge. Despite improved survival rates thanks to intensive chemotherapy regimens, event-free (EFS) and overall (OS) survival remains <70% and R/R T-ALL has a par...
2023-03-13 | Financiado
StemLinc: Identification and characterization of long non-coding RNAs as drivers of stemness in hematopoietic stem cells and leukemia. FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: Hematopoietic stem cells (HSCs) are a unique population defined by their self-renewal capacity and the potential to give rise to all blood lineages. A complete understanding of the specific mechanisms...
2022-07-13 | Financiado
SIRT7-LC: Role of the SIRT7-NPM-c-Myc pathway in lung cancer FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: Lung cancer is the second cause of death due to malignancy and diagnosed patients rarely survive beyond two years. Thus, unveiling the molecular mechanisms underlying lung tumorigenesis is imperative...
2022-06-29 | Financiado
ALERT: Contribution of Lipid Droplets to the pathogenesis and chemoresistance of Acute Myeloid Leukemia FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: Acute Myeloid Leukemia (AML) results from the uncontrolled expansion of differentiation-defective hematopoietic stem/progenitor cells or immature myeloid cells (blasts) in the bone marrow (BM). AML re...
2022-06-27 | Financiado
PROS-VARIANT: PIK3CA-Related Overgrowth Spectrum: molecular mechanisms and preclinical modelling of PIK3CA VARIANTs FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un H2020: PIK3CA-related overgrowth spectrum (PROS) is a group of rare congenital disorders that manifest as complex syndromes with overgrowth of several tissues (vasculature, adipose and muscle tissues, bones,...
2022-09-01 | Financiado
PLEC2022-009416: Desarrollo de una inmunoterapia innovadora adoptiva de células CAR-T para sarcoma de Ewing - CARITES FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un AEI: El sarcoma de Ewing (SE) es el segundo sarcoma óseo y de tejidos blandos más frecuente en personas menores de 40 años. La supervivencia a largo plazo de los pacientes con sarcoma de Ewing sigue siendo...
2022-01-01 | Financiado
GPE2022-001061: Impulsar el potencial del Instituto Josep Carreras para crecer internacionalmente FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un AEI: El Instituto de Investigación contra la Leucemia Josep Carreras (IJC) se fundó el 2010 con la misión de investigar los aspectos epidemiológicos, preventivos, clínicos, traslacionales y básicos de la l...
2022-01-01 | Financiado
PDC2022-133476-I00: ESTUDIO DE VALIDACION Y VALORIZACION EN EL MERCADO DE EPICART, UNA FIRMA PARA PREDECIR LA RESPUESTA A LA TERAPIA DE CELULAS CAR-T FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un AEI: LAS NEOPLASIAS DE CELULAS B SON UN GRUPO HETEROGENEO DE NEOPLASIAS DE UNA ALTA INCIDENCIA COMO LA LEUCEMIA, EL LINFOMA O EL MIELOMA. LAS TERAPIAS PARA LAS NEOPLASIAS MALIGNAS DE CELULAS B VARIAN SEGUN...
2022-01-01 | Financiado
SENAGE: Senescence as a key factor in leukemogenesis and bone marrow homeostasis in aging FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un H2020: Cancer is a major public health problem and one of the leading causes of death worldwide. In particular, it has been the second cause of death in Spain, Europe and United States. Although cancer can o...
2021-09-01 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.